[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100165429":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":7,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":57,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Closter Pharma","INDUSTRY",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Sandra M Casiano, MD","CONTACT","57-3174049763","scasiano@closterpharma.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Harold Mejia","57-2264757","hmejia@closterpharma.com",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Country Club de Bogota","RECRUITING","Bogotá","Colombia","CO",{"type":26,"coordinates":27},"Point",[28,29],-74.08175,4.60971,{"lat":29,"lon":28},[32],{"name":33,"role":34,"phone":7,"phoneExt":7,"email":7},"Andres Romero, MD","PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100165429","real-life-experience-of-the-use-of-isomers-as-metpure-xl-s---metoprolol-succinate-for-evaluation-of-efficacy-safety-and-tolerability-in-the-management-of-cardiovascular-disease-in-colombian-patients-100165429",false,"NCT01426594","Real-life Experience of the Use of Isomers as METPURE XL (S (-) Metoprolol Succinate) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients","XPERT","Inclusion Criteria:\n\n* Patients who were prescibed with s(-)metoprolol succinate(25mg, 50mg), depending on their clinical condition and use locally approved will be eligible to participate in this study","ALL","18 Years",{"count":47,"type":48},2000,"ESTIMATED","OBSERVATIONAL","This is a Phase 4, observational, open study in patients who their doctor has prescribe METPURE XL (S (-)metoprolol succinate)by clinical practice. No medication was provided by the sponsor. The planned observation time is 8 weeks. The 8 weeks of observation involves an evaluation of baseline followed by information gathered from the assessment visits at week 4 and week 8.",[52,53],"Hypertension","Coronary Disease",[55,23,56],"Observational","Metpure XL","UNKNOWN","2011-08-30",{"date":60,"type":48},"2011-08-31",{"date":62,"type":7},"2011-08",{"date":64,"type":48},"2012-03",{"name":5,"class":6},1]